KR102792934B1 - 세페타프로스트와 Rho 키나아제 저해제의 조합 의약 - Google Patents

세페타프로스트와 Rho 키나아제 저해제의 조합 의약 Download PDF

Info

Publication number
KR102792934B1
KR102792934B1 KR1020207020813A KR20207020813A KR102792934B1 KR 102792934 B1 KR102792934 B1 KR 102792934B1 KR 1020207020813 A KR1020207020813 A KR 1020207020813A KR 20207020813 A KR20207020813 A KR 20207020813A KR 102792934 B1 KR102792934 B1 KR 102792934B1
Authority
KR
South Korea
Prior art keywords
cepetaprost
rho kinase
kinase inhibitor
glaucoma
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207020813A
Other languages
English (en)
Korean (ko)
Other versions
KR20200103042A (ko
Inventor
야스코 야마모토
타카즈미 타니구치
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20200103042A publication Critical patent/KR20200103042A/ko
Application granted granted Critical
Publication of KR102792934B1 publication Critical patent/KR102792934B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207020813A 2017-12-21 2018-12-20 세페타프로스트와 Rho 키나아제 저해제의 조합 의약 Active KR102792934B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2017244847 2017-12-21
JPJP-P-2017-244847 2017-12-21
JP2018180658 2018-09-26
JPJP-P-2018-180658 2018-09-26
PCT/JP2018/046970 WO2019124488A1 (ja) 2017-12-21 2018-12-20 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Publications (2)

Publication Number Publication Date
KR20200103042A KR20200103042A (ko) 2020-09-01
KR102792934B1 true KR102792934B1 (ko) 2025-04-07

Family

ID=66993448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020813A Active KR102792934B1 (ko) 2017-12-21 2018-12-20 세페타프로스트와 Rho 키나아제 저해제의 조합 의약

Country Status (9)

Country Link
US (2) US11446273B2 (https=)
EP (2) EP4338751B1 (https=)
JP (2) JPWO2019124488A1 (https=)
KR (1) KR102792934B1 (https=)
CN (1) CN111479568A (https=)
CA (1) CA3086457A1 (https=)
ES (2) ES2972934T3 (https=)
TW (2) TWI788484B (https=)
WO (1) WO2019124488A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
KR20230051199A (ko) * 2020-08-13 2023-04-17 산텐 세이야꾸 가부시키가이샤 세페타프로스트를 함유하는 의약 제제
TW202404569A (zh) 2022-04-22 2024-02-01 日商參天製藥股份有限公司 含有賽佩普斯特(Sepetaprost)之眼科用組合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310370A1 (en) 2011-02-04 2013-11-21 Kowa Co., Ltd. Drug therapy for preventing or treating glaucoma

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
DE3871596T3 (de) 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
CA2307285C (en) 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP4342704B2 (ja) 2000-07-21 2009-10-14 富士フイルム株式会社 液晶分子の配向方法
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP4017921B2 (ja) 2002-06-12 2007-12-05 高砂熱学工業株式会社 暖房室内の空気循環装置
JP4128038B2 (ja) 2002-07-10 2008-07-30 富士フイルム株式会社 電子ペーパー
JP4482726B2 (ja) 2002-08-29 2010-06-16 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
EP1792622A1 (en) * 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP2010113957A (ja) 2008-11-06 2010-05-20 Ntt Docomo Inc コネクタ
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
JP2011013651A (ja) 2009-07-03 2011-01-20 Mitsumasa Maeda フレキシブルディスプレイのれん
RU2540330C2 (ru) 2009-07-28 2015-02-10 Оно Фармасьютикал Ко., Лтд. Бициклическое соединение и его применение для медицинских целей
JP5835236B2 (ja) 2011-01-27 2015-12-24 小野薬品工業株式会社 二環式化合物およびその医薬用途
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130310370A1 (en) 2011-02-04 2013-11-21 Kowa Co., Ltd. Drug therapy for preventing or treating glaucoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Arq. Bras. Oftalmol., 78(6), 388-391, 2015.*
Br. J. Ophthalmol., 100(3), 339-344, 2016.*
J. Glaucoma, 25(10), e826-e833, 2016.*

Also Published As

Publication number Publication date
WO2019124488A1 (ja) 2019-06-27
EP4338751A2 (en) 2024-03-20
US11446273B2 (en) 2022-09-20
TW201927298A (zh) 2019-07-16
EP3730138A1 (en) 2020-10-28
EP3730138A4 (en) 2021-08-25
US20220387372A1 (en) 2022-12-08
CA3086457A1 (en) 2019-06-27
US20200316009A1 (en) 2020-10-08
EP4338751C0 (en) 2025-09-03
TWI833535B (zh) 2024-02-21
ES2972934T3 (es) 2024-06-17
JPWO2019124488A1 (ja) 2020-12-17
KR20200103042A (ko) 2020-09-01
ES3041644T3 (en) 2025-11-13
EP4338751B1 (en) 2025-09-03
EP4338751A3 (en) 2024-05-22
EP3730138B1 (en) 2024-02-14
CN111479568A (zh) 2020-07-31
US12201602B2 (en) 2025-01-21
JP2023110030A (ja) 2023-08-08
TW202320747A (zh) 2023-06-01
TWI788484B (zh) 2023-01-01

Similar Documents

Publication Publication Date Title
US12201602B2 (en) Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor
JP6383058B2 (ja) スルホンアミド化合物の組み合わせ
WO2019124489A1 (ja) セペタプロストとｅｐ２アゴニストとの組み合わせ医薬
JPWO2019131901A1 (ja) ピリジルアミノ酢酸化合物を含有する医薬製剤
HK40102807A (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40102807B (en) Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
EA050493B1 (ru) ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ КОМБИНАЦИЮ СЕПЕТАПРОСТА И ИНГИБИТОРА Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ
EA043888B1 (ru) Лекарственное средство, содержащее комбинацию сепетапроста и ингибитора rho-ассоциированной протеинкиназы, содержащей суперспираль
HK40029829A (en) Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
HK40024494A (en) MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND Rho-KINASE INHIBITOR
KR20260016608A (ko) 오미데네팍의 조합
TWI917308B (zh) 歐米德尼培（Ｏｍｉｄｅｎｅｐａｇ）之組合
HK40029829B (en) Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
EA043474B1 (ru) Комбинация омиденепага
HK40025370A (en) Omidenepag combination
HK40029828A (en) Omidenepag combination
JP2012250952A (ja) アデノシン誘導体とＲｈｏキナーゼ阻害剤の組合せ剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211213

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250203

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250403

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250403

End annual number: 3

Start annual number: 1

PG1601 Publication of registration